The Federal Trade Commission continues to analyze relevant products that have not yet been introduced into the market in its merger analysis. In Medtronic Deal Highlights FTC Focus On Future Competition, we discuss the FTC's recent review of Medtronic's acquisition of Covidien, where the Commission looked over the horizon to see two apparent new entrants and took steps to ensure that even after the merger, there would still be two new competitors for the incumbent monopolist. It is clear that the agency is continuing to look at remedying forward-looking competitive concerns rather than simply remedying the present overlaps and concerns that may plague a potential acquisition.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
